文献速递泌尿生殖与妇科肿瘤放疗

中危前列腺癌大分割立体定向推量放疗:CKNO-PRO试验5年分析

A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-10-08

这项多中心2期研究纳入76例中危前列腺癌患者,先予46 Gy常规分割外照射,再予18 Gy(3×6 Gy)立体定向体部放疗推量。5年生化无复发生存率为87.4%,≥2级泌尿和胃肠毒性累积发生率分别为1.4%和9.3%,耐受性良好且疗效可观。

要点

  • 中危前列腺癌外照射后SBRT推量5年耐受性良好。
  • 5年生化无复发生存率87.4%,无复发生存率86.2%。
  • 60个月≥2级泌尿毒性1.4%,胃肠毒性9.3%。

核心结论

  • 外照射联合SBRT推量耐受性良好且疗效结果可观。
  • 该数据为未来前瞻性研究比较外照射联合近距离放疗推量与联合SBRT推量提供基础。

研究设计与样本

  • 多中心2期研究,2010年8月至2013年4月纳入76例中危前列腺癌患者。
  • 第一疗程常规分割外照射46 Gy,第二疗程10天内SBRT推量18 Gy(3×6 Gy)。
  • 60例(79%)采用CyberKnife,16例(21%)采用直线加速器。
  • 中位随访62个月(范围29-69)。

主要发现

  • 放疗结束后60个月≥2级泌尿毒性累积发生率为1.4%(95%CI 0.1%-6.6%)。
  • 放疗结束后60个月≥2级胃肠毒性累积发生率为9.3%(95%CI 4.1%-17.1%)。
  • 5年生化无复发生存率为87.4%(95%CI 77.1%-93.2%),无复发生存率为86.2%(95%CI 75.8%-92.3%)。
  • 放疗后3个月内和5年时PSA平均变化分别为-1.20 ng/mL/月(标准差0.79)和-1.30 ng/mL/年(标准差1.05)。

关键数值与推荐

  • 毒性按美国国家癌症研究所常见不良事件术语标准v4.0评估。
  • 功能状态采用国际勃起功能指数和国际前列腺症状评分问卷评估。

临床怎么用

  • 中危前列腺癌可采用外照射46 Gy后SBRT推量18 Gy(3×6 Gy)的方案,需关注胃肠毒性及性功能变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this analysis was to assess the 5-year tolerance and survival in patients undergoing hypofractionated stereotactic boost after external beam radiation therapy (EBRT) for intermediate-risk prostate cancer. METHODS AND MATERIALS: Between August 2010 and April 2013, 76 patients with intermediate-risk prostate carcinoma were included in the study. A first course delivered 46 Gy using conventional fractionation. The second course delivered a boost of 18 Gy (3 × 6 Gy) within 10 days using stereotactic body radiation therapy (SBRT). Gastrointestinal and genitourinary toxicities were assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v4.0. Secondary outcome measures were overall, biochemical relapse-free, and relapse-free survival; prostate-specific antigen kinetics; and patient functional status (urinary and sexual) according to the International Index of Erectile Function and International Prostate Symptom Score questionnaires. RESULTS: Sixty patients (79%) were treated by CyberKnife and 16 (21%) by linear accelerator. Median follow-up was 62 months (range, 29-69). The cumulative incidence of genitourinary and gastrointestinal grade ≥2 toxicities at month 60 after the end of radiation therapy was 1.4% (95% confidence interval [CI], 0.1%-6.6%) and 9.3% (95% CI, 4.1%-17.1%), respectively. Biochemical relapse-free and relapse-free survival rates at 5 years were 87.4% (95% CI, 77.1%-93.2%) and 86.2% (95% CI, 75.8-92.3), respectively. The mean (standard deviation) prostate-specific antigen variation within 3 months and 5 years post-radiation therapy was -1.20 ng/mL/mo (0.79) and -1.30 ng/mL/y (1.05), respectively. There was no significant difference between the International Prostate Symptom quality of life score between inclusion and month 60. For the International Index of Erectile Function, there was a significant difference between inclusion and month 60 (P = .005), with a higher proportion of severe/noninterpretable disorders at 60 months. CONCLUSIONS: The results of the trial demonstrate that the EBRT and SBRT combination is well tolerated and yields good efficacy results. These data provide a good basis for comparing EBRT and brachytherapy boost to EBRT and SBRT boost in future prospective studies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pasquier D, Peiffert D, Nickers P, et al. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 31604131. doi:10.1016/j.ijrobp.2019.09.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。